Syntrix Biosystems, Inc.
Clinical trials sponsored by Syntrix Biosystems, Inc., explained in plain language.
-
New drug combo targets Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study tests a new drug called SX-682, alone or with another drug (decitabine), in people with myelodysplastic syndrome (MDS), a type of blood cancer. The main goal is to find the safest dose and understand side effects. About 151 adults whose MDS has not responde…
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New hope for men with hard-to-treat prostate cancer? drug combo enters trial.
Disease control Recruiting nowThis study tests a combination of two drugs, SX-682 and enzalutamide, in 53 men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the combo can shrink tumors, lower PSA levels, or keep the disease…
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC